Loading
Senior investigator behind CCTG's breast cancer trials, including the MA.17 and MA.32 studies of extended endocrine therapy and metformin.
Wendy Parulekar is Senior Investigator at the Canadian Cancer Trials Group and Professor of Oncology at Queen's University. She is the senior investigator behind the group's breast cancer trials, having led or co-led MA.17R, which tested extended adjuvant letrozole, and MA.32, which tested metformin, and she oversees the group's trial operations. Her publications include the MA.17R trial of extending aromatase-inhibitor adjuvant therapy to ten years. Her interests are breast cancer, clinical trial conduct and endocrine therapy.
| Title | Journal | Year |
|---|---|---|
| Extending aromatase-inhibitor adjuvant therapy to 10 years (MA.17R) | NEJM | 2016 |
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
Shares Letrozole (and other aromatase inhibitors), Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.